补阳还五汤联合环磷酰胺治疗儿童激素抵抗性肾病综合征23例  被引量:7

BuYang HuanWu Tang Combined with Cyclophosphamide in the Treatment 23 Cases of Children with Steroid Resistant Nephrotic Syndrome

在线阅读下载全文

作  者:杨世霞[1] 康娟[1] YANG Shixia;KANG Juan(Department of nephropathy, Gansu Provincial Hospital of Taditional Chinese Medicine, Lanzhou 730050, China)

机构地区:[1]甘肃省中医院肾病科,甘肃兰州730050

出  处:《西部中医药》2017年第4期99-101,共3页Western Journal of Traditional Chinese Medicine

摘  要:目的:观察补阳还五汤联合磷酰胺治疗儿童激素抵抗性肾病综合征的短期疗效。方法:将47例患儿随机分为观察组23例、对照组24例。2组均给予强的松及环磷酰胺治疗;观察组在对照组治疗的基础上加用补阳还五汤,水煎分服,1剂/d。2组均以治疗4周为1个疗程,连续治疗4个疗程。观察2组临床疗效及药物副反应发生情况。结果:总缓解率对照组为54.17%,观察组为82.60%,2组比较差异有统计学意义(P<0.05)。2组副反应发生率比较,差异有统计学意义(P<0.05)。结论:补阳还五汤联合环磷酰胺能够提高激素抵抗性肾病综合征患者的缓解率,降低药物副反应。Objective:To observe the short-term curative effect of BuYang HuanWu Tang combined withcyclophosphamide in the treatment of children with steroid resistant nephrotic syndrome(NS).Methods:47cases were randomly divided into the observation group(n=23)and the control group(n=24).The two groups were treated with prednisone and cyclophosphamide,the observation group was treated with BuYang HuanWu Tang with water decocted and graded oral administration,once everyday.The two groups were treated for four weeks for a course of treatment and four courses of the continuous treatment.The clinical efficacy and side effects of the two groups were observed.Results:The total remission rate was54.17%in the control group while the observation group was82.60%.The difference between the two groups was statistically significant(P<0.05).There was significant difference in the incidence of side effects between the two groups(P<0.05).Conclusion:BuYang HuanWu Tang combined with cyclophosphamide can increase the remission rate of patients with steroid resistant nephritic syndrome,and reduce the adverse drug reaction.

关 键 词:肾病综合征 激素抵抗性 补阳还五汤 环磷酰胺 儿童 

分 类 号:R692[医药卫生—泌尿科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象